SLC5A2 and chronic kidney disease: The level of evidence for benefit of SGLT2 inhibitors is greatest for patients with or without established atherosclerotic cardiovascular disease but with HFrEF (left ventricular ejection fraction (LVEF) < 40%) or CKD (eGFR 30–60 mL/min per 1.73 m2 or urine albumin:creatinine ratio (UACR) > 30 mg/g, particularly when UACR ≥ 300 mg/g).